Nature Medicine

News

13 Sep 2022
A commentary in Nature Medicine advocates the proper application of artificial intelligence in healthcare and warns of the dangers when machine learning algorithms are misused.
21 Jan 2022
A booster dose of the Pfizer–BioNTech vaccine (BNT162b2) against SARS-CoV-2 after an initial two doses of either the CoronaVac inactivated virus vaccine or Pfizer–BioNTech mRNA vaccine is shown to provide protection against the Omicron variant, in a pair of papers published in Nature Medicine.
21 Oct 2020
Although most people are likely to accept a future vaccine against COVID-19 if one is proven safe and efficacious, the hesitancy of those who refuse vaccination could stall global efforts to achieve community immunity, suggests a study published in Nature Medicine.
29 May 2020
An international collaborative team from PROS Ehime University and CellFee Science, Japan; the Walter and Eliza Hall Institute, Australia; Pasteur Institute, France; and Foundation for Innovative New Diagnostics, Switzerland developed a new diagnostic blood test which detects recent exposure to ‘vivax’ malaria. The new test can also identify people who may harbor dormant liver-stage malaria parasites, which can cause illness. This new diagnostic approach has the potential to enhance malaria surveillance and accelerate elimination.
18 May 2020
Professor Tony MOK from the Faculty of Medicine of The Chinese University of Hong Kong (CU Medicine) and Professor LU You from West China School of Medicine at The Sichuan University co-led the world’s first-in-human Phase I clinical trial investigating the safety and feasibility of CRISPR gene-edit therapy as a treatment option for patients with late stage lung cancer. Research team recruited 22 advanced Non-small-cell lung carcinoma (NSCLC) patients and isolate the T cell (a form of white blood cell) from peripheral blood. After gene-editing by CRISPR, the T cells that were reinfused back to patient may have the ability to attack cancer cell. Objective of the study is to demonstrate safety and feasibility. Results demonstrated CRISPR technology is safe and feasible as patients showed no severe adverse events and the frequency of off-target events was only 0.05%. This opens a new chapter in the history of lung cancer immunotherapy. The findings were recently published on-line in the international medical journal Nature Medicine.
22 Jan 2020
A new compound could help doctors detect epileptic foci in the living human brain as well as further the understanding of psychiatric disease.

Events

Sorry, no events coming up for this topic.

Researchers

Sorry, no researchers coming up for this topic.

Giants in history

Sorry, no researchers coming up for this topic.